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AbstrACt
Objective To determine whether methodological and 
reporting quality are associated with surrogate measures 
of publication impact in the field of dementia biomarker 
studies.
Methods We assessed dementia biomarker studies 
included in a previous systematic review in terms of 
methodological and reporting quality using the Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS) and 
Standards for Reporting of Diagnostic Accuracy (STARD), 
respectively. We extracted additional study and journal-
related data from each publication to account for factors 
shown to be associated with impact in previous research. 
We explored associations between potential determinants 
and measures of publication impact in univariable and 
stepwise multivariable linear regression analyses.
Outcome measures We aimed to collect data on 
four measures of publication impact: two traditional 
measures—average number of citations per year and 
5-year impact factor of the publishing journal and two 
alternative measures—the Altmetric Attention Score and 
counts of electronic downloads.
results The systematic review included 142 studies. 
Due to limited data, Altmetric Attention Scores and 
electronic downloads were excluded from the analysis, 
leaving traditional metrics as the only analysed outcome 
measures. We found no relationship between QUADAS 
and traditional metrics. Citation rates were independently 
associated with 5-year journal impact factor (β=0.42; 
p<0.001), journal subject area (β=0.39; p<0.001), 
number of years since publication (β=-0.29; p<0.001) and 
STARD (β=0.13; p<0.05). Independent determinants of 
5-year journal impact factor were citation rates (β=0.45; 
p<0.001), statement on conflict of interest (β=0.22; 
p<0.01) and baseline sample size (β=0.15; p<0.05).
Conclusions Citation rates and 5-year journal impact 
factor appear to measure different dimensions of impact. 
Citation rates were weakly associated with completeness 
of reporting, while neither traditional metric was related 
to methodological rigour. Our results suggest that high 
publication usage and journal outlet is not a guarantee of 
quality and readers should critically appraise all papers 
regardless of presumed impact.
IntrOduCtIOn 
Arguably, the greatest recent advances and 
greatest controversies in dementia manage-
ment have been around diagnosis. A partic-
ular area that has generated excitement 
in both lay and scientific press is the use of 
dementia biomarkers. A biomarker has been 
defined as ‘a characteristic that can be objec-
tively measured and evaluated as an indicator 
of normal biological or pathogenic processes 
or pharmacological responses to a thera-
peutic intervention’.1 
In theory, biomarker results from midlife 
can predict later life dementia. Putative 
dementia biomarkers, including proteins 
in cerebrospinal fluid (CSF) and neuroim-
aging techniques are gaining traction in clin-
ical practice and have been recognised in 
new dementia diagnostic criteria.2 However, 
there is a concern that enthusiasm and 
uptake of these technologies is premature 
strengths and limitations of this study
 ► Studies included were identified through a compre-
hensive, systematic search.
 ► A range of different potential determinants of publi-
cation impact was considered for analysis, selected 
based on findings from previous research.
 ► Due to limited data, alternative metrics could not be 
used as an outcome measure.
 ► An analysis of the context in which a paper was cit-
ed was not conducted.
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and the supporting evidence may not be sufficiently 
robust.3
The scientific assessment of diagnostic test accuracy 
(DTA) is a field that has historically been prone to meth-
odological limitations and biases.4 This has been partic-
ularly true in the area of dementia research. The DTA 
landscape is evolving. With an aim to improve design, 
conduct, reporting, assessment and comparison of DTA 
studies, best practice guidance such as the Quality Assess-
ment of Diagnostic Accuracy Studies (QUADAS) and 
Standards for Reporting of Diagnostic Accuracy (STARD) 
have been developed.5 6
QUADAS consists of a checklist of 14 items to consider 
when assessing potential bias arising from methodolog-
ical limitations in DTA studies. The tool aims to capture 
aspects relating to internal and external validity. It was 
derived through a Delphi procedure,7 informed by two 
systematic reviews—the first looking at potential sources 
of bias and variation in DTA studies8 and the second 
focusing on existing quality assessment tools.9 STARD is a 
25-item checklist, developed following an extensive liter-
ature search. Its purpose is to support evaluation of the 
completeness and accuracy of study reporting in DTA.
As well as methodological and reporting quality, 
another way to quantify the ‘success’ of a scientific paper 
is to measure impact. For scientific data to effect change, 
the results need to reach the appropriate audience and 
then inform subsequent research, policy or practice. 
The importance of the construct of broader impact is 
increasingly recognised by government, universities 
and funding bodies. However, methods to measure or 
quantify impact remain open to interpretation with no 
consensus definition. Impact can operate at many levels 
and there is a difficulty in assigning a single definition to 
this multidimensional construct.10 As it is challenging, or 
in some cases impossible, to directly estimate how a single 
publication has influenced current thought and inspired 
advances in research and policy change, impact is typi-
cally assessed using surrogate measures.
Traditional surrogate measures of impact have involved 
the use of citation-based metrics, particularly citation 
counts for the individual paper and the impact factor of 
the journal it is published in. Citation counts are assumed 
to reflect the received attention and usage of a paper 
within a scientific community, while publication in a 
journal with a high impact factor is often assumed to indi-
cate adherence to strict requirements and high journal 
standards, as well as recognition by peer reviewers.11
In more recent years, with the advent of electronic 
publication and usage, academic and public social media, 
there has been a growing interest in ‘Altmetrics’—an alter-
native method of assessing publication impact.12 Altmet-
rics aim to quantify the digital reads, online mentions and 
usage of research papers, some beyond the boundaries of 
scientific publishers and communities. Gathering infor-
mation from social media, blogs and mainstream news 
outlets, Altmetrics are considered to have two important 
advantages—allowing insight into how much attention 
scientific outputs receive from the general public and 
almost immediately providing means of evaluating impact 
without the delays associated with acquiring citations.
One would assume that scientific papers indicated 
to have the highest impact in terms of traditional and 
alternative metrics would also be the papers with the 
highest quality of reporting and methodological rigour. 
However, reports from certain research areas suggest that 
this is not necessarily the case.13–16 This is an important 
issue, as papers with high visibility and usage are likely to 
influence the direction of future research, clinical prac-
tice and healthcare policy. Given the volume of recent 
original research concerning dementia biomarkers and 
the substantial interest some of these publications have 
generated, we felt that dementia biomarkers would be a 
useful ‘substrate’ to expand the description of the associ-
ation between measures of study quality and quantitative 
measures of study impact.
study objective
The overall aim of this study was to assess whether meth-
odological quality and completeness of reporting in 
dementia biomarker papers, assessed using the QUADAS 
and STARD checklists, respectively, was associated with 
traditional and alternative metrics of impact. Recog-
nising the complexity and variability of influences on 
publication impact, we additionally explored other plau-
sible factors that could influence impact and described 
whether reporting and study quality had independent 
associations with the various traditional and contempo-
rary measures of impact.
MethOds
study search and selection
Our data collection and analysis followed a preregis-
tered protocol (reviewregistry89 in Registry of Systematic 
Reviews/Meta-Analyses; http://www. researchregistry. 
com). We performed a Medline search in collaboration 
with an information scientist from Cochrane Dementia 
to identify papers on dementia biomarkers published 
between January 2000 and August 2011. We chose this 
time horizon to allow sufficient time for all included 
studies to acquire citations to evaluate potential impact. 
The full search strategy is provided in the supplementary 
materials (see online supplementary appendix 1) or alter-
natively can be found at: http://www. medicine. ox. ac. uk/ 
alois/ content/ diagnostic- test- accuracy- search- strategy.
Biomarkers of interest included β-amyloid and tau 
levels in CSF and results from positron emission tomog-
raphy and MRI. We included studies with a longitudinal 
design, involving participants who at baseline had objec-
tive cognitive impairment with no dementia. Two assessors 
independently rated the quality of the included primary 
studies, using the primary versions of both the QUADAS 
and STARD tools. Both checklists having undergone revi-
sion and newer versions are available, used the earlier iter-
ations as these would have been the benchmark measures 
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of methodological quality and reporting at the time the 
papers were published. We have described the search 
strategy, study selection process and quality assessment in 
detail previously.3
Variables
With the aim to investigate the relationship between 
study quality and measures of impact, we considered 
total QUADAS and STARD scores, calculated as the 
sum of individual item scores, the main determinants of 
interest. However, we recognised additional variables as 
being related to quality, reliability and generalisability 
of research evidence, including: total number of partic-
ipants at baseline, number of participants with dementia 
at the end of a study, reporting of quantitative accuracy 
measures (eg, sensitivity, specificity) and providing a 
statement on COI.
We included two further variables in view of the specific 
research area of analysed studies—type of biomarker 
used (CSF, neuroimaging) and use of data from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI).17 18 
Although the latter does not directly imply differences in 
study content or quality, ADNI has received substantial 
financial support from both public and private sectors, 
is considered an influential project with a high number 
of associated publications, and a model for similar 
programmes subsequently developed worldwide.19 Thus 
it appeared plausible that reported use of ADNI data may 
be associated with increased publication impact.
We also considered a group of potentially confounding 
variables in view of findings from other areas of research, 
reporting on a number of factors influencing publication 
impact, despite their lack of association with study quality. 
This involved: study location (North America vs Europe, 
Africa, Asia, Australia and South America),20 funding 
source (industry vs academia),13 journal subject area 
(neuroscientific vs multidisciplinary or other research 
area),21 and authors’ conclusions,22 here specifically 
relating the utility of the investigated biomarker (posi-
tive vs neutral and negative). Finally, as citation rates 
are considered to be a time-dependent measure,23 we 
also included the number of years since publication as a 
potential determinant.
We were initially interested in analysing four outcome 
measures. Two were traditional impact metrics – average 
number of citations per year since the paper’s year of 
publication and 5 year impact factor of the publishing 
journal. We collected these data using Web of Science 
citation reports (Clarivate Analytics). As a third 
measure, we chose an alternative metric, reflecting the 
attention a publication receives in social media24 25 – the 
Altmetric Attention Score, determined using the Book-
marklet tool.26 The final outcome measure we consid-
ered for the analysis related to counts of electronic 
reads/downloads reported by journal websites. A full 
list of the variables is provided with definitions in the 
supplementary materials (see online supplementary 
appendix 2).
A single researcher (SM) collected study-level data and 
impact data, with a random selection (20%) cross-checked 
by an independent researcher (TQ). An exception was 
made for categorising authors’ conclusions on biomarker 
utility and journal subject area, having recognised that 
these tasks may be prone to subjectivity. Therefore, both 
researchers assessed each included study on these vari-
ables independently, with discrepancies discussed and 
resolved through consensus. The publishing journals 
were categorised based on their name in all cases where 
it provided a clear indication of the journal’s subject area 
(eg, Radiology, Neurology). If the subject area could not be 
directly inferred from the name (eg, Brain, JAMA), cate-
gorisation was based on the journal’s own description of 
its scope, as presented on its website’s home page.
statistical analysis
We used Spearman correlation coefficients and Mann-
Whitney U tests to explore univariable associations 
between the outcome measures and continuous and 
dichotomous determinants, respectively. As this entailed 
performing multiple tests (15 per outcome measure), we 
adjusted the critical alpha level using the Holm-Bonfer-
roni technique,27 which allows to reduce the possibility of 
a Type I error, while offering increased power as compared 
with the Bonferroni method. For interpreting observed 
effect sizes, we used the Rule of Thumb, presented in 
Applied Statistics for Behavioural Sciences (fifth edition).28
Following these procedures, we conducted multivari-
able linear regression analyses for each measure of publi-
cation impact. When assessed, we found that assumptions 
on linear relationships between variables and lack of 
multicollinearity were met. However, an inspection of 
scatterplots and normal probability plots of residuals 
revealed violations of the assumptions on homoscedas-
ticity and normality of error distribution. Therefore, we 
applied a natural log transformation to the dependent 
variables. A subsequent inspection of plots indicated that 
both assumptions were satisfied.
With mean citation rates and 5 year journal impact 
factor likely being related, when we entered one impact 
measure into the analysis as an outcome, we included the 
other as one of the explanatory variables to account for 
its contribution to the variance of the former. We chose a 
stepwise regression method, which allowed us to compute 
the most parsimonious linear model by adding only vari-
ables that significantly increase its explanatory value, 
while removing variables that become non-significant as 
others are added. We conducted all analyses using SPSS 
(Version 22, IBM).
results
The search strategy identified 19 104 research publi-
cations, of which we found 142 eligible for inclusion. 
References for these studies are provided in online supple-
mentary appendix 3 in the supplementary materials. We 
were able to extract complete study data on variables 
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of interest for all but two included papers – one, where 
we could not determine the number of patients with 
dementia at the end of follow-up, and one, where there 
was no report on the impact factor for the publishing 
journal. We excluded these two studies only from analyses 
involving variables with the missing values. Independent 
validation of extracted data revealed no errors in results 
recorded. Extracted study data, as well as QUADAS and 
STARD scores, are presented for each individual publica-
tion in the supplementary materials (see online supple-
mentary appendix 4 and 5, respectively).
We found that counts of electronic reads/downloads 
were available from only a few platforms, and therefore we 
did not pursue this analysis. Similarly, we did not include 
Altmetric Attention Scores as an outcome measure, due 
to only 15% of the studies having a score greater than 0 
(M=0.67; SD=2.16; range: 0–14)
Table 1 presents descriptive data for the included 
studies. In relation to key variables of interest, studies on 
average obtained a QUADAS score of 8.9, with a lowest 
score of 3 and a highest of 12, meaning that none of the 
studies satisfied all 14 checklist items. The average STARD 
score was 16.1, with a minimum of 7 and a maximum of 
25 – the highest possible score, which was obtained by 
four studies. We observed relatively large variability 
in terms of traditional metrics. The mean for average 
number of citations per year was 12.8, with a minimum 
of 0.4 and maximum of 117.7, while on average the 5 year 
journal impact factor was 6.1, with a lowest value of 1.2 
and highest of 33.6.
Results from univariable analyses are presented in 
table 2. Having applied the Holm-Bonferroni correction, 
we found no significant association between measures of 
methodological and reporting quality and either studied 
measure of impact. We observed that a higher average 
number of citations per year was weakly associated with 
papers being more recent, as well as published in a 
neuroscientific journal. Neuroscientific journal subject 
area was also very weakly associated with 5 year journal 
impact factor, together with papers including a statement 
on COI and a North American study location. However, 
overall, the strongest positive correlation we observed, 
at a moderate level, was between the two measures of 
impact.
Results of the linear regression only partially reflected 
the observed univariable associations. The most parsi-
monious model for explaining variance in the average 
number of citations per year involved four of the consid-
ered variables: 5 year journal impact factor (β=0.42; 
P<0.001), journal subject area (β=0.34; P<0.001), number 
of years since publication (β=−0.29; P<0.001) and 
total STARD score (β=0.13; P<0.05); (F(4, 135)=32.81, 
P<0.001, R2=0.49). While a model incorporating three 
variables explained the greatest proportion of variance 
in 5 year journal impact factor (F(3, 136)=20.47, P<0.001, 
R2=0.31), although here it included: average number of 
citations per year (β=0.45; P<0.001), statement addressing 
COI (β=0.22; P<0.01), and total number of study partici-
pants at baseline (β=0.15; P<0.05).
dIsCussIOn
Across a substantial literature describing the test accu-
racy of dementia biomarkers, we found that citation rates 
varied considerably, with some studies showing relatively 
high impact in terms of traditional metrics. At the same 
time, the methodological and reporting quality of studies, 
measured using the QUADAS and STARD tools respec-
tively, was on average quite low. We found little evidence 
of an association between traditional measures of paper 
impact and its reporting or methodological quality.
Although we found that STARD scores were an inde-
pendent determinant of the average number of citations 
per year, the association was very weak, with journal char-
acteristics explaining considerably more of the variance. 
These findings are consistent with results from previous 
studies in other fields of clinical research, where either 
limited or no association was found between citation rates 
and indicators of quality.29–31
In addition, we did not observe any significant rela-
tionship between the quality checklist scores and 5 year 
journal impact factor. The latter was however very weakly 
associated with the total number of study participants, 
a factor impacting on the precision of diagnostic accu-
racy estimates.32 There was also a weak association with 
the inclusion of a statement on conflict of interest (COI), 
Table 1 Descriptive statistics of study level and impact 
data
QUADAS score (range 0–14), mean (±SD) 8.9 (±1.5)
STARD score (range 0–25), mean (±SD) 16.1 (±4.0)
Baseline sample size, mean (±SD) 171.3 (±288.2)
No. of participants with dementia at end of 
study, mean (±SD)*
47.3 (±50.4)
Report on biomarker accuracy, n (%) 52 (36.6)
Statement on COI, n (%) 52 (36.6)
CSF biomarker, n (%) 56 (39.4)
Imaging biomarker, n (%) 102 (71.8)
ADNI study population, n (%) 11 (7.7)
North American study location, n (%) 60 (42.3)
Pharmaceutical funding source, n (%) 12 (8.5)
Neuroscientific journal, n (%) 85 (59.9)
Positive authors’ conclusions, n (%) 122 (85.9)
No. of years since publication, mean (±SD) 9.1 (±3.0)
Average no. of citations per year, mean 
(±SD)
12.8 (±15.5)
5-year journal impact factor, mean (±SD)* 6.1 (±3.9)
*Data from 141 studies.
ADNI, Alzheimer’s Disease Neuroimaging Initiative; COI, conflict 
of interest; CSF, cerebrospinal fluid; QUADAS, Quality Assessment 
of Diagnostic Accuracy Studies checklist; STARD, Standards for 
Reporting of Diagnostic Accuracy checklist.
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which plays an important role in supporting research 
integrity.33
The finding that, unlike in the case of STARD, QUADAS 
scores were not related with either of the analysed impact 
measures, may partially be due to the assessment of meth-
odological quality being dependent on completeness of 
reporting. In cases of Inadequate reporting, the quality 
of study methods may easily be misjudged, and in turn, 
the estimated association between methodological quality 
and study impact distorted.
The study results may appear concerning, yet one could 
argue that finding any relationship whatsoever between 
citation rates and indicators of quality is a positive sign. 
We recognise that a proportion of papers included in our 
study were published at a similar period, or even previ-
ously, to the QUADAS and STARD checklists, and some 
time is required before new guidelines become widely and 
fully incorporated into research practice. These quality 
tools should inform all aspects of a research project from 
study design, through manuscript publication, to external 
assessment. We hope that the current generation of DTA 
studies is making greater use of these tools and that we 
will see the published outputs soon.
There is no ‘gold standard’ measure of impact. For 
reasons of practicality, impact is typically assessed indi-
rectly, through surrogate measures, which was also the 
case in the present study. However, the appropriate-
ness of using traditional metrics for the evaluation of 
scientific output has been strongly questioned.10 34 35 
These measures are criticised for susceptibility to bias 
(eg, related to language of publication) and risk of 
overlooking important differences in context, relating 
both to norms within specific research fields, as well as 
motives for citation. Journal impact factor in particular 
is argued to offer a poor representation of usage for 
an individual paper, being based on averaging across 
multiple publications, often with very skewed citation 
distributions and citation rates.10 21 36 Our results appear 
to confirm that individual paper citation rates and 
journal impact factor measure different dimensions of 
impact, with one explaining little variance within the 
other and different variables contributing to the two 
final models.
Despite the limitations of traditional metrics, they are 
still often used to evaluate the achievements of research 
groups and institutions and are considered for the 
purposes such as promotion and funding allocation.11 34 
An increasing number of researchers are voicing their 
concerns regarding this practice and suggest that quanti-
tative measures be used only to support qualitative expert 
assessment,34 35 allowing a more accurate evaluation of 
a study’s novelty and its contribution to a specific field 
of research and practice. If impact were to be assessed 
in this advocated way, it is possible that a stronger asso-
ciation would be found between publication impact and 
its methodological and reporting quality. However, as 
long as traditional metric remain the primary method 
of assessing publication impact, it is important that even 
Table 2 Univariable associations between publication and journal characteristics and measures of impact
Average citations per year 5-year journal impact factor
Effect size (r) P value Effect size (r) P value
QUADAS score 0.12 0.144 0.04 0.670
STARD score 0.18 0.035 0.02 0.797
Baseline sample size 0.05 0.522 0.17 0.040
No. of participants with dementia 
at end of study
0.11 0.190 0.13 0.120
Report on biomarker accuracy 0.11 0.187 0.07 0.384
Statement on COI 0.11 0.204 0.28 0.001*
CSF biomarker 0.07 0.410 0.04 0.646
Imaging biomarker 0.09 0.301 0.10 0.251
ADNI population 0.17 0.046 0.21 0.012
Continent 0.19 0.024 0.29 0.001*
Funding 0.15 0.084 0.18 0.031
Journal subject area 0.46 <0.001* 0.28 0.001*
Authors’ conclusions 0.03 0.707 0.06 0.500
No. of years since publication −0.32 <0.001* −0.05 0.562
Average no. of citations per year – – 0.63 <0.001*
5-year journal impact factor 0.63 <0.001* – – 
*P value indicating a significant association after applying a Holm-Bonferroni correction.
ADNI, Alzheimer’s Disease Neuroimaging Initiative; COI, conflict of interest; CSF, cerebrospinal fluid; QUADAS, Quality Assessment of 
Diagnostic Accuracy Studies checklist; STARD, Standards for Reporting of Diagnostic Accuracy checklist.
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papers with presumed high impact are scrutinised in 
terms of their quality.
Strengths of this study involve following best practice 
in conducting our analysis of associations and including 
a variety of potential determinants of publication impact, 
selected in view of previous research findings.37 38 We 
further performed a comprehensive and explicit publi-
cation search, aided by the Cochrane group. One of the 
limitations, however, is that this search focused on one 
database only (Medline), potentially increasing the risk 
of missing relevant papers. As our purpose was to assess a 
range of sources with a spread of impact, it is not such a 
concern if the search was not completely comprehensive. 
The titles returned were however similar to the search 
results from a more comprehensive Cochrane review of 
biomarkers.39 40
Another important limitation of this and similar studies 
is that due to restricted time and resources, we did not 
conduct an analysis of citation context. Although papers 
are typically referenced in view of the evidence they 
provide in support of a particular hypothesis, they may 
also be mentioned in a perfunctory way, summarising 
methods or even in a negative way. This variability in cita-
tion context may partially explain why the relationship 
between measures of impact and study quality appears 
so modest, and it is possible that a stronger association 
would be found if only references made in a positive 
context were to be considered.
Finally, we included studies published up until August 
2011. Although the time elapsed from publication was 
sufficient for acquiring citations, providing a good oppor-
tunity for measuring citation-based impact, the asso-
ciations we studied may have been subject to gradual 
change, for example, due to increasing endorsement of 
best practice guidelines. This may limit the applicability 
of our findings in view of more recent studies. A related 
issue is that, due to lack of sufficient data, we were not 
able to investigate the relationship between measures 
of quality and contemporary, alternative metrics. As 
altmetrics are relatively new, it has been suggested that 
indeed this measure has little usefulness when assessing 
papers published before 2011,41 which was the case in the 
present study. With research evidence indicating at most a 
moderate relationship between citation rates and altmet-
rics,41–43 it seems that these two metrics reflect somewhat 
different kinds of impact and therefore may be affected 
by different variables.
Future research should investigate whether the associ-
ation with indicators of study quality is different for alter-
native metrics, reflecting online mentions and digital 
reads than for traditional measures of impact, focusing 
on citation counts and the impact factor of publishing 
journals. This would necessitate analysing more recent 
publications, where it is recommended to use the revised 
versions of QUADAS and STARD checklists for quality 
assessment—QUADAS-2, STARD 2015 and STARDem, 
the latter having dementia-specific guidance.44–46 An 
additional advantage of an updated analysis would be 
the possibility of assessing whether the introduction and 
promotion of quality checklists has resulted over time in 
strengthening associations between measures of study 
quality and any relevant measures of publication impact—
traditional and alternative, quantitative and qualitative.
COnClusIOn
Findings from this study indicate that publication in a 
presumed high-impact journal or frequent citation is no 
guarantee that a paper is methodologically robust. Clini-
cians, researchers and policy-makers should critically 
appraise all published evidence regardless of impact. An 
assessment of study quality should further accompany the 
use of traditional metrics when evaluating the scientific 
impact of research work within academic institutions. To 
improve methodological and reporting quality of future 
studies, it is important that researchers and authors 
adhere to current best practice guidelines, while journal 
editors mandate submitting manuscripts accompanied by 
completed quality checklists.
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